Your session is about to expire
← Back to Search
CAB IR Formulation (reference)/CAB DT Formulation (Test 1)/CAB DT Formulation (Test 2) for Human Immunodeficiency Virus Infection
Study Summary
This trial tests how well a medicine works, and if it works differently when taken with food.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Does the protocol for this investigation encompass participants over fifty-five years of age?
"This medical trial is recruiting participants that are 18 years and older, but younger than 55."
Can I be part of this medical experiment?
"Eligibility for this trial necessitates HIV infection and an age range between 18 to 55. This research is presently recruiting 24 participants."
Are participants being recruited for this experiment currently?
"Reportedly, patient recruitment for this medical trial is ongoing. It was first advertised on March 23rd 2023 and the most recent update occurred April 20th of that same year."
What potential health risks could be associated with CAB IR Formulation (reference)/CAB DT Formulation (test 2)/CAB DT Formulation (test 1)?
"CAB IR Formulation (reference)/CAB DT Formulation (test 2)/CAB DT Formulation (test 1) have been assigned a safety score of 1 as this is its first clinical trial; therefore, there are limited data available in regard to its efficacy and security."
How many individuals are eligible for participation in this experiment?
"Affirmative. As per the clinicaltrials.gov website, this medical trial began recruitment on March 23rd 2023 and is currently open for applications. The study requires 24 volunteers from a single location to fill its ranks."
Share this study with friends
Copy Link
Messenger